Heatwurx (NASDAQ:PCSA) Upgraded by Wall Street Zen to Sell Rating

Heatwurx (NASDAQ:PCSA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Other analysts also recently issued research reports about the company. Zacks Research downgraded Heatwurx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a report on Wednesday, October 8th. Finally, HC Wainwright lowered their price objective on shares of Heatwurx from $50.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, September 2nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

Heatwurx Trading Down 3.1%

NASDAQ:PCSA opened at $3.78 on Friday. The firm has a market capitalization of $8.58 million, a PE ratio of -0.11 and a beta of 1.09. Heatwurx has a 1 year low of $2.74 and a 1 year high of $27.00. The firm’s fifty day simple moving average is $7.34 and its 200 day simple moving average is $6.37.

Heatwurx (NASDAQ:PCSA) last released its earnings results on Thursday, November 6th. The company reported ($1.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.25. As a group, analysts anticipate that Heatwurx will post -4.05 EPS for the current fiscal year.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.